Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial

DISEASE CHARACTERISTICS:

• Patients or their parents/guardians (if patient is a minor) consented to participate in a phase I treatment clinical trial with an optional pharmacokinetic (PK) component, within the past 4 weeks

  • Must not have withdrawn consent for the phase I treatment study

    • Patients or their parents/guardians are eligible regardless of whether they initially agreed to participate in the PK sampling

      • Must not withdraw consent for PK sampling prior to completing the study questionnaire if initially agreed to optional PK sampling
    • Patients or their parents/guardians are eligible regardless of whether they actually completed PK sampling (provided reasons for not completing the sampling was not withdrawal of the initial consent to the phase I treatment study)

PATIENT CHARACTERISTICS:

• Not cognitively or physically impaired
• May participate no more than once in the study questionnaire survey

PRIOR CONCURRENT THERAPY:

• No limit on participation in the number of prior phase I trials or other studies